Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC9A1 | P19634 | 2/20 | 0.41 |
| ▸ | ICMT | O60725 | 7/20 | 0.40 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.39 |
| ▸ | RXRA | P19793 | 1/20 | 0.39 |
| ▸ | PPARG | P37231 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.36 |
| ▸ | PKM | P14618 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | CSNK1D | P48730 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | ABL1 | P00519 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2393136 | 0.85 | SLC9A1 (0.42) | SLC9A1ICMTSMN1; SMN2PKMMAPT | |
| SCHEMBL9890752 | 0.83 | SMN1; SMN2 (0.42) | RXRAPPARGSMN1; SMN2PKMMAPT | |
| SCHEMBL9890710 | 0.82 | FFAR1 (0.43) | SLC9A1ICMTMAPT | |
| SCHEMBL2394997 | 0.82 | DPP4 (0.40) | ICMTMAPK14PKM | |
| SCHEMBL12265632 | 0.82 | CHRM1 (0.46) | ICMTMAPT | |
| SCHEMBL9890790 | 0.82 | PKM (0.40) | SLC9A1ICMTSMN1; SMN2PKMMAPT | |
| SCHEMBL9892664 | 0.80 | CHRM5 (0.41) | ICMTMAPTLMNA | |
| SCHEMBL2090788 | 0.79 | ICMT (0.46) | SLC9A1ICMT | |
| SCHEMBL2395132 | 0.79 | ICMT (0.39) | SLC9A1ICMTPPARGMAPT | |
| SCHEMBL2393938 | 0.78 | KCNA5 (0.37) | ICMTPKMLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120142771-A1 | BIPHENYLACETAMIDE DERIVATIVE | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2012-06-07 | — | — | US | disclosed |
| US-20110224304-A1 | BIPHENYLACETAMIDE DERIVATIVE | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2011-09-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120142771-A1 | BIPHENYLACETAMIDE DERIVATIVE | HRH3, KCNH3, BRPF3 | SLC9A1 132/4885ICMT 2894/4885MAPK14 1382/4885 |
| US-20110224304-A1 | BIPHENYLACETAMIDE DERIVATIVE | HRH3, KCNH3, BRPF3 | SLC9A1 132/4885ICMT 2894/4885MAPK14 1382/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.